Versant Venture Capital V L.P. 13D and 13G filings for Repare Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-01-06 4:19 pm Sale | 2022-12-29 | 13D | Repare Therapeutics Inc. RPTX | Versant Venture Capital V L.P. | 2,094,451 5.000% | -250,000 (-10.66%) | Filing |
| 2022-06-13 4:38 pm Sale | 2022-06-03 | 13D | Repare Therapeutics Inc. RPTX | Versant Venture Capital V L.P. | 2,344,451 5.600% | -250,000 (-9.64%) | Filing |
| 2021-08-16 4:57 pm Unchanged | 2021-08-05 | 13D | Repare Therapeutics Inc. RPTX | Versant Venture Capital V L.P. | 2,594,451 7.000% | 0 (Unchanged) | Filing |
| 2021-02-26 4:36 pm Sale | 2021-02-16 | 13D | Repare Therapeutics Inc. RPTX | Versant Venture Capital V L.P. | 2,594,451 7.100% | -550,000 (-17.49%) | Filing |
| 2021-01-25 4:27 pm Sale | 2021-01-14 | 13D | Repare Therapeutics Inc. RPTX | Versant Venture Capital V L.P. | 3,144,451 8.600% | -275,000 (-8.04%) | Filing |
| 2020-07-06 9:31 pm Purchase | 2020-06-23 | 13D | Repare Therapeutics Inc. RPTX | Versant Venture Capital V L.P. | 3,419,451 9.300% | 3,419,451 (New Position) | Filing |